The Benefits of Using Continuous Glucose Monitoring to Diagnose Type 1 Diabetes

Abstract

Keywords

CGM islet autoantibody stage 2 T1D teplizumab T1D

Get full access to this article

View all access options for this article.

References

Gong

Yang

Xing

Lai

Shan

. Global, regional, and national burden of type 1 diabetes in adolescents and young adults [published online ahead of print March 5, 2024]. Pediatr Res. doi:10.1038/s41390-024-03107-5.

Joish

Zhou

Preblick

, et al. Estimation of annual health care costs for adults with type 1 diabetes in the United States. J Manag Care Spec Pharm. 2020;26(3):311-318. doi:10.18553/jmcp.2020.26.3.311.

Wersäll

Adolfsson

Forsander

Ricksten

Hanas

. Delayed referral is common even when new-onset diabetes is suspected in children. A Swedish prospective observational study of diabetic ketoacidosis at onset of type 1 diabetes. Pediatr Diabetes. 2021;22(6):900-908. doi:10.1111/pedi.13229.

Umpierrez

Davis

ElSayed

, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47(8):1257-1275. doi:10.2337/dci24-0032.

Taplin

Barker

. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41(1):11-18. doi:10.1080/08916930701619169.

Parkkola

Härkönen

Ryhänen

Ilonen

Knip

; Finnish Pediatric Diabetes Register. Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. Diabetes Care. 2013;36(2):348-354. doi:10.2337/dc12-0445.

Kontola

Alanko

Koskenniemi

, et al. Exploring minimally invasive approach to define stages of type 1 diabetes remotely. Diabetes Technol Ther. 2022;24(9):655-665. doi:10.1089/dia.2021.0554.

Keam

. Teplizumab: first approval. Drugs. 2023;83(5):439-445. doi:10.1007/s40265-023-01847-y.

Sims

Bundy

Stier

, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):1-14. doi:10.1126/scitranslmed.abc8980.

10.

Phillip

Achenbach

Addala

, et al. Consensus guidance for monitoring individuals with islet autoantibody–positive pre-Stage 3 type 1 diabetes. Diabetes Care. 2024;47(8):1276-1298. doi:10.2337/dci24-0042.

11.

Karakuş

Sakarya

Yeşiltepe Mutlu

, et al. Benefits and drawbacks of continuous glucose monitoring (CGM) use in young children with type 1 diabetes: a qualitative study from a country where the CGM is not reimbursed. J Patient Exp. 2021;8:1-7. doi:10.1177/23743735211056523.

12.

Bergenstal

Ahmann

Bailey

, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7(2):562-578. doi:10.1177/193229681300700234.

13.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.

14.

Steck

Dong

Taki

Hoffman

Klingensmith

Rewers

. Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes. Diabetes Care. 2014;37(7):2031-2033. doi:10.2337/dc13-2965.

15.

Belgian Diabetes Registry; Van Dalem

Demeester

Balti

, et al. Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. Diabetologia. 2015;58(12):2753-2764. doi:10.1007/s00125-015-3761-y.

16.

Helminen

Pokka

Tossavainen

Ilonen

Knip

Veijola

. Continuous glucose monitoring and HbA1c in the evaluation of glucose metabolism in children at high risk for type 1 diabetes mellitus. Diabetes Res Clin Pract. 2016;120:89-96. doi:10.1016/j.diabres.2016.07.027.

17.

Steck

Dong

Taki

, et al. Continuous Glucose Monitoring Predicts Progression to Diabetes in Autoantibody Positive Children. J Clin Endocrinol Metab. 2019;104(8):3337-3344. doi:10.1210/jc.2018-02196.

18.

Steck

Dong

Geno Rasmussen

, et al. CGM metrics predict imminent progression to type 1 diabetes: autoimmunity screening for kids (ASK) study. Diabetes Care. 2022;45(2):365-371. doi:10.2337/dc21-0602.

19.

Wilson

Pietropaolo

Acevedo-Calado

, et al. CGM metrics identify dysglycemic states in participants from the trialnet pathway to prevention study. Diabetes Care. 2023;46(3):526-534. doi:10.2337/dc22-1297.

20.

Ylescupidez

Speake

Pietropaolo

, et al. OGTT metrics surpass continuous glucose monitoring data for t1d prediction in multiple-autoantibody–positive individuals. J Clin Endocrinol Metab. 2023;109(1):57-67. doi:10.1210/clinem/dgad472.